Specific chemotherapeutic agents induce metastatic behaviour through stromal‐ and tumour‐derived cytokine and angiogenic factor signalling
- 19 May 2015
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 237 (2) , 190-202
Abstract
Recent studies reveal that chemotherapy can enhance metastasis due to host responses, such as augmented expression of adhesion molecules in endothelial cells and increased populations of myeloid cells. However, it is still unclear how tumour cells contribute to this process. Here, we observed that paclitaxel and carboplatin accelerated lung metastasis in tumour‐bearing mice, while doxorubicin and fluorouracil did not. Mechanistically, paclitaxel and carboplatin induced similar changes in cytokine and angiogenic factors. Increased levels of CXCR2, CXCR4, S1P/S1PR1, PlGF and PDGF‐BB were identified in the serum or primary tumour tissues of tumour‐bearing mice treated by paclitaxel. The serum levels of CXCL1 and PDGF‐BB and the tissue level of CXCR4 were also elevated by carboplatin. On the other hand, doxorubicin and fluorouracil did not induce such changes. The chemotherapy‐induced cytokine and angiogenic factor changes were also confirmed in gene expression datasets from human patients following chemotherapy treatment. These chemotherapy‐enhanced cytokines and angiogenic factors further induced angiogenesis, destabilized vascular integrity, recruited BMDCs to metastatic organs and mediated the proliferation, migration and epithelial‐to‐mesenchymal transition of tumour cells. Interestingly, inhibitors of these factors counteracted chemotherapy‐enhanced metastasis in both tumour‐bearing mice and normal mice injected intravenously with B16F10–GFP cells. In particular, blockade of the SDF‐1α–CXCR4 or S1P–S1PR1 axes not only compromised chemotherapy‐induced metastasis but also prolonged the median survival time by 33.9% and 40.3%, respectively. The current study delineates the mechanism of chemotherapy‐induced metastasis and provides novel therapeutic strategies to counterbalance pro‐metastatic effects of chemo‐drugs via combination treatment with anti‐cytokine/anti‐angiogenic therapy. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- General Programs of the National Natural Science Foundation of China (81171998, 81272529, 81472667, 81461148021)
- Major Scientific and Technological Special Project for Significant New Drugs Creation (No. 2011ZX09101-001-08 and No. 2013ZX09509103)
This publication has 45 references indexed in Scilit:
- Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapiesOncogene, 2013
- Cyclophosphamide Creates a Receptive Microenvironment for Prostate Cancer Skeletal MetastasisCancer Research, 2012
- Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in MiceCancer Research, 2011
- Chemotherapy Enhances Metastasis Formation via VEGFR-1–Expressing Endothelial CellsCancer Research, 2011
- Chemotherapy counteractedNature, 2010
- Peering into the aftermath: The inhospitable host?Nature Medicine, 2010
- DNA Damage-Mediated Induction of a Chemoresistant NicheCell, 2010
- Cyclophosphamide Enhances Human Tumor Growth in Nude Rat Xenografted Tumor ModelsNeoplasia, 2009
- Induction of Cancer Metastasis by Cyclophosphamide Pretreatment of Host Mice: An Opposite Effect of ChemotherapyCancer Research, 2008
- The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisitedNature Reviews Cancer, 2003